1. Sager PT, Gintant G, Turner JR, Pettit S, Stockbridge N. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium. Am Heart J. 2014;167:292–300.
2. CiPA Update Workshop: an CSRC-HESI-SPS-FDA Meeting. http://www.cardiac-safety.org/think-tanks-meetings/2014-meetings/cipa-update-workshop-csrc-hesi-sps-fda-meeting/. Published December 2014. Accessed June 29, 2018.
3. CSRS/FDA Workshop: the proarrhythmic assessment of new chemical entities (with a focus on Phase I ECGs). April 2016. http://www.cardiac-safety.org/2016/04/csrcfda-workshop-the-proarrhythmic-assessment-of-new-chemical-entities/. Accessed June 29, 2018.
4. CSRC. Critical discussion: future of the assessment of drug-induced arrhythmias and the Comprehensive in Vitro Proarrhythmia Assay (CiPA). http://www.cardiac-safety.org/2016/12/critical-discussion-future-of-the-assessment-of-drug-induced-arrhythmias-and-the-comprehensive-in-vitro-proarrhythmia-assay-cipa/. Published December 2016. Accessed June 29, 2018.
5. FDA. Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting, March 2017. https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/ucm535520.htm. Accessed June 29, 2018.